REGN Latest Press Releases

-- April 29, 2026 --

Regeneron Reports First Quarter 2026 Financial and Operating Results Globe Newswire 6:30 AM

-- April 23, 2026 --

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. Globe Newswire 3:46 PM

Otarmeni (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. Globe Newswire 12:40 PM

-- April 22, 2026 --

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Globe Newswire 5:30 PM

Dupixent (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) Globe Newswire 5:30 PM

-- April 21, 2026 --

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial Globe Newswire 10:30 AM

-- April 20, 2026 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- April 13, 2026 --

Regeneron and Telix Announce Strategic Radiopharma Collaboration Globe Newswire 6:30 AM

Telix and Regeneron Announce Strategic Radiopharma Collaboration Globe Newswire 6:30 AM

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Globe Newswire 1:00 AM

Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) Globe Newswire 1:00 AM

-- April 2, 2026 --

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions Globe Newswire 4:30 PM

EYLEA HD (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Globe Newswire 12:00 PM

-- March 25, 2026 --

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 Globe Newswire 4:05 PM

-- March 24, 2026 --

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Globe Newswire 2:00 AM

Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) Globe Newswire 2:00 AM

-- March 10, 2026 --

Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment Globe Newswire 9:29 PM

-- March 9, 2026 --

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients Globe Newswire 7:00 AM

-- March 5, 2026 --

Regeneron Announces Investor Conference Presentation Globe Newswire 4:05 PM

-- March 3, 2026 --

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight PRNewswire 5:31 PM

-- February 27, 2026 --

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment Globe Newswire 7:03 AM

Dupixent (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment Globe Newswire 7:00 AM

-- February 26, 2026 --

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders Globe Newswire 12:00 PM

-- February 24, 2026 --

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Globe Newswire 9:30 AM

Dupixent (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) Globe Newswire 9:30 AM

-- February 19, 2026 --

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Globe Newswire 7:00 AM

-- February 17, 2026 --

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight PRNewswire 5:31 PM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- February 11, 2026 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- February 10, 2026 --

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy Globe Newswire 7:00 AM

-- February 2, 2026 --

EYLEA HD (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases Globe Newswire 7:00 AM

-- January 30, 2026 --

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Globe Newswire 6:30 AM

-- January 21, 2026 --

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search Globe Newswire 12:00 PM

-- January 2, 2026 --

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 Globe Newswire 4:05 PM

-- December 7, 2025 --

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment Globe Newswire 4:30 PM